Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. Offered by National Institutes of Health; applications due January 7, 2027.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- Not specified by funder
- Deadline
- January 7, 2027
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The...
Full requirements and application instructions: official listing.
Similar Open Grants
Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)
National Institutes of Health
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
National Institutes of Health
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
National Institutes of Health
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
National Institutes of Health
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
National Institutes of Health
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
National Institutes of Health
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health
NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
National Institutes of Health